Ambrilia, ZBx Extend Agreement for Rights to Prostate Cancer Diagnosis Technology

Ambrilia Biopharma Inc. announced Monday that it has extended the exclusive license option agreement with ZBx Corporation that granted ZBx the worldwide rights to develop, manufacture and commercialize Ambrilia’s PSP94 technology in ZBx’s Zap Rapid Test System and Assays.
TradingMarkets